Huey-Wen Hsiao

Huey-Wen Hsiao

Auto-generated profile, based on publicly available information

Huey-Wen Hsiao

Elixiron Immunotherapeutics Inc., Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Cancer Discovery
Verified
Journal Article
Closed access
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
Tumor cells develop various strategies to evade immune surveillance, one of which involves altering the metabolic state of the tumor microenvironment. In response to metabolic stress in the tumor microenvironment, several tumor-infiltrating immune subsets upregulate CD36 to take up lipids. This leads to impaired antitumor immunity, as intratumoral regulatory T cells exhibit increased survival and suppressive activity, whereas CD8+ T cells become more susceptible to ferroptosis and exhaustion. In this study, we develop a humanized anti-CD36 IgG4 antibody, PLT012, against the lipid-binding domain of CD36 with excellent safety and favorable pharmacokinetic features in mice and cynomolgus monkeys. PLT012 alone or in combination with PD-L1 blockade or standard-of-care immunotherapy results in robust antitumor immunity in both immunotherapy-sensitive and -resistant hepatocellular carcinomas (HCC). Notably, PLT012 also reprograms the immune landscape of human HCC ex vivo. Our findings provide proof-of-concept evidence that PLT012 reprograms antitumor immunity in HCC, positioning it as a first-in-class immunotherapy targeting CD36. Significance: Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.

4 August 2025
Verified
Other
Open access
PDF file
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
In vivo distribution assay for PLT012 treatment in HCC mouse model.

4 August 2025
Verified
Other
Open access
PDF file
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
Characterization for TILs population and gene signatures in liver cancer mouse models following PLT012 treatment.

4 August 2025
Verified
Other
Open access
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
Table S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

4 August 2025
Verified
Other
Open access
PDF file
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
An in silico analysis on POG570 to evaluate the potential of PLT012 in targeting metastatic diseases.

4 August 2025
Verified
Other
Open access
PDF file
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
Characterization of the progression and immune profile of the MYCOE /CTNNB1N90 liver cancer mouse model in the context of lipid-rich condition.